SPOTLIGHT: Billionaire doubles VC funds

Billionaire David Murdock has doubled his commitment to a venture capital fund designed to lure drug developers to a research campus he's developing in North Carolina. He's now devoting $200 million to the venture fund. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.